Last updated: July 27, 2026
Isosorbide Mononitrate Clinical Trials Update, Market Analysis, and Revenue Projections (2026–2035)
Executive summary: Isosorbide mononitrate (ISMN) is a long-established, off-patent antianginal nitrate available in multiple generics. Current clinical-trials activity is limited and fragmented, with no clear signal of a near-term, high-enrollment phase-3 program that would materially change market structure. Commercially, ISMN’s market is driven by maintenance angina and dosing convenience of extended-release products, with competitive pressure from low-cost generics and combination formulations. Revenue growth is likely modest, trackable primarily through volume stabilization, price erosion dynamics, and periodic formulation renewals in selected geographies rather than new molecular-entity approvals.
What clinical trials are active for isosorbide mononitrate right now?
Featured snippet answer: Active ISMN clinical trials, where present, typically fall into small-to-moderate pharmacokinetic (PK), bioequivalence (BE), real-world adherence/tolerability, or formulation-comparison studies rather than registrational late-stage trials. Any near-term “pipeline shift” is more likely to come from improved-release platforms and new dosing regimens than from new therapeutic indications.
Clinical-trials pattern by trial type
Common ISMN study categories
- BE and PK: Extended-release vs reference product; tablet integrity; food-effect assessments; salt/formulation comparisons.
- Tolerability and adherence: Once-daily vs divided dosing; symptom diaries for chronic stable angina cohorts.
- Special populations: Hepatic impairment, renal impairment, older adult PK and tolerability.
Why this matters for projections
- Registrational phase-3 trials that drive market expansion are uncommon for off-patent nitrates.
- Most near-term changes in sales come from product lifecycle management (PLCM): reformulation, line extensions, and regional launches of generic BE-compliant products.
How many total isosorbide mononitrate clinical trials exist, and what phases are they in?
Featured snippet answer: The trial set is dominated by non-registrational studies. The “phase” distribution skews toward Phase 1/2 PK and BE-style protocols, with relatively few active Phase 3 programs for new indications.
How to interpret trial volume for an off-patent drug
- Higher counts often reflect bioequivalence submissions and formulation studies, not clinical innovation.
- Fewer late-stage trials indicates limited probability of a new regulatory label expansion that would reset market size.
When will isosorbide mononitrate generics face meaningful competitive shifts?
Featured snippet answer: Competitive shifts for ISMN generally occur when (1) major generic launches occur in specific markets, (2) pricing resets post-launch, and (3) payers prefer specific extended-release SKUs that demonstrate consistent clinical performance or simpler dosing.
Key timing drivers
- Patent and exclusivity reality: Most ISMN actives are off original exclusivity in major markets, so the competitive frontier is usually label-equivalence + BE + pricing.
- Formulation adoption cycles: Extended-release and once-daily products can win formulary slots even without new clinical endpoints.
- Regional approvals: Markets with later generic uptake can show stepwise growth even while global growth stays muted.
Is isosorbide mononitrate still protected by meaningful patents, and does that affect clinical development?
Featured snippet answer: ISMN is generally off-patent for the active ingredient in major jurisdictions, so patent protection typically exists only for specific formulations, manufacturing processes, or method-of-use claims. This reduces the incentive for large phase-3 development programs by new entrants.
Patent estate typical impact (commercial)
- Market entrants rely on BE and formulary access.
- Development focus shifts to product differentiation that is not necessarily label-changing.
(No Orange Book or jurisdiction-specific listing was provided in the prompt, so this analysis treats protection as structurally limited in major markets rather than enumerating specific patent numbers.)
What is the Orange Book status of isosorbide mononitrate products in the US?
Featured snippet answer: The US market for ISMN is mostly served by multiple approved generic extended-release and immediate-release products. The Orange Book typically lists numerous ANDA products with earlier-established approvals and limited remaining exclusivity.
Commercial consequence
- Competitive dynamics are dominated by:
- pricing,
- procurement contracts,
- copay tiers,
- and payer preferences for specific dosage forms.
How does isosorbide mononitrate market size evolve, and what is the price erosion profile?
Featured snippet answer: ISMN is a mature antianginal with a low growth ceiling. Revenue changes track primarily with:
- unit volume growth (population and persistence in angina management),
- partial substitution within nitrate classes,
- and aggressive price erosion typical of generic oral therapies.
Market drivers
- Stable angina prevalence and chronic use patterns.
- Adherence benefits for once-daily or extended-release formulations.
- Payer pressure toward the lowest-cost AB-rated products.
Market headwinds
- Generic price compression.
- Therapeutic substitutions toward other antianginal regimens (when tolerability or comorbidities favor alternatives).
- Nitrate tolerance management protocols that affect dosing cadence in practice.
Which formulations of isosorbide mononitrate have the strongest commercial position?
Featured snippet answer: Extended-release is typically the largest revenue contributor because it aligns with once- or twice-daily maintenance regimens and formulary preferences for dosing simplicity.
Formulation segmentation to use for forecasting
- Extended-release tablets/capsules: Chronic prophylaxis and maintenance.
- Immediate-release tablets: More often used for titration, breakthrough patterns, or where extended-release is not tolerated.
- Dose strength mix: Higher-strength penetration often correlates with adherence and physician preference, but does not eliminate price pressure.
What is the competitive landscape for isosorbide mononitrate in 2026?
Featured snippet answer: Competition is primarily between multiple generic manufacturers selling AB-rated oral nitrates, with occasional differentiation by extended-release design, tablet geometry, or manufacturing scale. Brand-level competition is limited.
Typical market structure
- Numerous ANDA filers.
- Most products compete on cost, availability, and contract terms.
- Switching is payer-led, pharmacy-led, or procurement-led depending on geography.
How much revenue can isosorbide mononitrate generate from 2026 to 2035?
Featured snippet answer: Expect low single-digit revenue growth in mature markets and stepwise growth in markets with later generic uptake. Growth is constrained by generic price compression.
Projection framework (used for decision-grade modeling)
Because the prompt provides no geographic baseline (current sales, WAC, or units), a business-grade projection must be expressed as a scenario model rather than a single-point number.
Scenario set (global / major markets)
- Base case: 0% to +3% CAGR revenue through 2035
- modest volume growth offset by continued price erosion
- Upside case: +3% to +5% CAGR
- faster volume stabilization, better extended-release mix, fewer supply disruptions
- Downside case: -1% to +1% CAGR
- intensified procurement-driven switching to lower-cost SKUs and deeper price compression
What changes the curve most
- Extended-release share gain.
- Gross-to-net shifts from contracting and wholesaler incentives.
- Generic price floors in US vs ex-US.
- Any supply disruptions that temporarily lift prices.
Where is market growth most likely for isosorbide mononitrate?
Featured snippet answer: Growth is most likely where generic penetration is still ramping, formularies are tightening around low-cost oral antianginals, and extended-release dosing uptake is increasing.
Geography-driven mechanisms
- Later generic uptake creates a sales step function.
- National reimbursement policies can drive rapid consolidation to a few contracted suppliers.
- Healthcare system procurement determines whether volume shifts are matched by unit price decreases.
What generic entry risks exist for isosorbide mononitrate products?
Featured snippet answer: For ISMN, the key “entry risk” is less about patent litigation and more about:
- BE program success,
- manufacturing and supply continuity,
- and payer/formulary acceptance.
In the absence of meaningful active exclusivity, the competitive barrier is economic and operational.
Practical entry blockers
- Tight contract procurement windows.
- Limited formulary slots for multiple AB products.
- Manufacturing capacity and regulatory quality track record.
What patent litigation affects isosorbide mononitrate?
Featured snippet answer: Large, recurring patent litigation is less typical for ISMN as an active ingredient compared with newer cardiometabolic or oncology assets. Any disputes tend to be formulation- or product-specific.
Commercial implication
- Litigation is unlikely to be the dominant driver of market timing.
- Forecast timing should instead be anchored to generic procurement cycles and contract renewals.
Does isosorbide mononitrate have biosimilar risk?
Featured snippet answer: No. ISMN is a small-molecule nitrate. Biosimilar pathways are not applicable.
How does isosorbide mononitrate compare with isosorbide dinitrate and other antianginal nitrates?
Featured snippet answer: ISMN is typically favored for once- or twice-daily maintenance due to pharmacokinetic handling and dosing convenience. Isosorbide dinitrate often faces similar generic price pressure but can differ in dosing schedules and patient preference.
Competitive substitution logic
- If extended-release ISMN is lower cost than comparable nitrate alternatives, it retains maintenance share.
- If tolerance or adherence issues arise, clinicians may adjust nitrate timing or switch agents within the antianginal regimen.
Key compliance and regulatory milestones that influence sales
Featured snippet answer: For off-patent oral generics, sales are more sensitive to:
- approval and labeling consistency,
- manufacturing compliance,
- and supply continuity
than to new regulatory milestone events.
Milestones to monitor
- ANDA approvals (new entrants and line extensions).
- BE waivers vs full BE studies (where relevant by jurisdiction).
- Recalls, stability issues, or GMP actions that can disrupt market availability.
Key Takeaways
- ISMN’s clinical-trials landscape is expected to skew toward BE/PK and formulation work rather than label-expanding late-stage development.
- Market growth is constrained by generic competition; revenue trajectories depend on extended-release mix and pricing/procurement dynamics.
- Projection range for global/major markets is typically low single-digit or flat through 2035, with stepwise gains where generic penetration is still ramping.
- Competitive risk is primarily economic and operational rather than patent-driven.
- Biosimilar risk does not apply.
FAQs
1) Are there any phase 3 clinical trials for isosorbide mononitrate in new indications?
Clinical activity is usually limited to non-registrational studies for off-patent nitrates; label-expanding phase 3 programs are uncommon.
2) Does extended-release isosorbide mononitrate have better market outcomes than immediate-release?
Typically yes, due to once- or twice-daily maintenance convenience and payer/formulary preferences.
3) What endpoints are most common in isosorbide mononitrate clinical studies?
PK/BE metrics, symptom diary outcomes for chronic angina cohorts, and tolerability/adherence measures.
4) What drives short-term revenue fluctuations for isosorbide mononitrate?
Generic procurement contracting, gross-to-net changes, and supply availability.
5) Is there litigation-driven delay risk for generic isosorbide mononitrate launches?
For the active ingredient, litigation is generally less central than for newer patented drugs; product-specific formulation disputes are the more plausible driver.
References (APA)
- ClinicalTrials.gov. (n.d.). Search results for isosorbide mononitrate trials. https://clinicaltrials.gov
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency. (n.d.). Medicines: Isosorbide mononitrate. https://www.ema.europa.eu
